Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Intarcia on the Verge of a Revolutionary Diabetes Drug

By Drug Discovery Trends Editor | May 10, 2016

​Intarcia Therapeutics, a Boston-based drug maker worth a whopping $5.5 billion, announced on Friday top-line results for its Phase 3 cardiovascular safety study of its type 2 diabetes treatment.

The investigational therapy is named ITCA 650, a GLP-1 receptor agonist administered through a small injectable pump embedded within the skin, according to Fortune. This process only takes a few minutes and needs to be performed one to two times per year eliminating the need for arduous daily or weekly injections.

More than 4,000 type 2 diabetes patients took part in this placebo-controlled global study over the course of three years. The purpose of this experiment was to assess the potential cardiovascular risk of type 2 diabetes therapies.

The proctors of the study tested 60 micrograms of the drug versus placebo. Average treatment durations lasted 1.2 years with a total of 160 major adverse cardiac events reported.

However, Intarcia’s release specified “the overall safety and tolerability data for ITCA 650 was consistent with the three Phase 3 trials that have already been presented and what is documented in the published literature,” regarding similar GLP-1 receptor agonists.

Next, Intarcia will aim for an FDA filing at the end of July and raised $75 million to fund manufacturing efforts if the FDA grants approval. ITCA 650 would be the first GLP-1 therapy capable of delivering a full year of treatment through an osmotic mini-pump if it’s able to reach market.

Plus, Intarcia would be able to capitalize on a lucrative opportunity. A July 2015 report from business intelligence provider GBI Research projects that the market for these therapeutics will reach $39 billion by 2021 due to benefits like easier administration methods and rising prevalence of the disease. 

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community! Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE